Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05384223 · ClinicalTrials.gov registry record · NA

Evaluation of RRFT for Co-occurring SUD and PTSD Among Teens

A NA study of PTSD and Substance Use Disorders, sponsored by Medical University of South Carolina.

Active
Registry status
NA
Development phase
212
Enrollment target
2
Study locations

NCT05384223 is a NA study of PTSD and Substance Use Disorders that is active but no longer recruiting, run by Medical University of South Carolina. The registered enrollment target is 212 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05384223, a NA study of PTSD and Substance Use Disorders, is active but no longer recruiting, sponsored by Medical University of South Carolina.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
212 participants
Enrollment target
2
Study locations

Study Summary

Psychosocial traumatic events during childhood, serve as strong and consistent predictors of substance use problems (SUP) during adolescence and adulthood.PTSD that extends from such trauma often co-occurs with SUP. Despite this well-established link, standard care for adolescents with co-occurring SUP and PTSD for the last several decades has been to treat these problems separately. This compartmentalized approach to treatment creates a burden on teens and families, raises unique challenges to clinicians in both mental health and addiction domains, and may contribute to high rates of SUP relapse among adolescents with co-occurring PTSD. To address this problem, our team recently completed a rigorous National Institute on Drug Abuse (NIDA)-funded randomized controlled trial (RCT) supporting the efficacy of an integrative, exposure-based treatment we developed, Risk Reduction through Family Therapy (RRFT), in greater long term reductions in SUP, as well as PTSD avoidance and hyperarousal symptoms, in comparison to standard treatment in a large teen sample. The proposed RCT, with an effectiveness-implementation Hybrid Type I design, substantially builds on that prior research by proposing to 1) evaluate whether RRFT's clinical effectiveness for reducing SUP and PTSD can be extended to youth in outpatient substance use treatment settings-where youth are presenting for SUP treatment and where clinicians often have less experience treating PTSD (Aim 1); 2)evaluate the cost-effectiveness of RRFT and to explore inner context variables (e.g., perceived treatment acceptability, attitudes, and satisfaction among the participating adolescents, caregivers, agency leaders, and therapists and barriers to and facilitators of implementation) that might affect RRFT implementation in diverse practice settings(Aim 2). The proposed effectiveness-implementation trial will recruit adolescents (13-18 years) with a history of psychosocial trauma presenting with SUP and PTSD symptoms for ou

Interventions

  • BEHAVIORAL RRFT (Risk Reduction through Family Therapy)
  • BEHAVIORAL ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)

Study Locations (2)

Colorado

  • CU Medicine Psychiatry - Outpatient Clinic - Aurora
  • ARTS - Synergy Outpatient Services - Denver

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2022-10-15
Est. Completion 2027-02-28
Phase NA

What the Registry Record Tells You About NCT05384223

The ClinicalTrials.gov registry entry for NCT05384223 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (30% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which RRFT (Risk Reduction through Family Therapy) is the first listed.

NCT05384223 reports 2 study locations spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05384223 about?

NCT05384223 is a clinical study titled "Evaluation of RRFT for Co-occurring SUD and PTSD Among Teens". Psychosocial traumatic events during childhood, serve as strong and consistent predictors of substance use problems (SUP) during adolescence and adulthood.PTSD that extends from such trauma often co-occurs with SUP. Despite this well-established link, standard care for adolescents with co-occurring ...

What is the current status of trial NCT05384223?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 212 participants. The study started on 2022-10-15. Estimated completion is 2027-02-28.

What conditions does trial NCT05384223 study?

This clinical trial studies the following conditions: PTSD, Substance Use Disorders.

What interventions are being tested in trial NCT05384223?

The interventions under investigation include: RRFT (Risk Reduction through Family Therapy) (BEHAVIORAL), ENCOMPASS (Integrated Treatment for Adolescents and Young Adults) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05384223?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05384223 being conducted?

This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.